IP Library Granted Patent US 12,559,504
Granted Patent B2
US 12,559,504 · App. 17/614,941 · Granted Feb 24, 2026

Benzotriazole derivative

Inventors: Ken-ichi Komori (Ube, JP); Hayato Nishiyama (Ube, JP); Naoya Kinoshita (Ube, JP); Yukinori Wada (Ube, JP); Kousuke Morishita (Ube, JP); Akishi Ninomiya (Ube, JP); Yuusuke Shiraishi (Ube, JP); Kazuhiro Onuma (Ube, JP); Sayaka Ogi (Ube, JP); Hiroyoshi Kawada (Ube, JP); Tomio Kimura (Shinagawa-ku, JP)
Assignee: UBE CORPORATION
C07D498/04A61P1/16C07D413/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,504
App. No.
17/614,941
Granted
Feb 24, 2026
Kind
B2
Abstract

The present invention provides a compound having Keap1 inhibitory effects and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein the symbols have the same meanings as those described in the description] or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

Claims (304)

1 . A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

R represents a hydrogen atom or an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 1 and R 2 each independently represent a hydrogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkenyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or an alkynyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 3 , R 4 , and R 6 each independently represent a hydrogen atom, a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkenyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkynyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a cycloalkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a nonaromatic heterocyclyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an aryl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a heteroaryl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or a cyano group;

R 5 represents (i) a hydrogen atom, or (ii) an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, a hydroxy group, a cycloalkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a phenyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, and an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

A has a structure represented by the following formula (II)

R 7 and R 8 each independently represent a hydrogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkenyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or an alkynyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

ring B represents a bicyclic ring optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkenyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkynyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a cycloalkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a nonaromatic heterocyclyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an aryl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, a heteroaryl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, and a cyano group;

the symbol

represents the point of attachment to the rest of molecule; and

Group E represents a group consisting of a halogen atom, a hydroxy group, and an alkoxy group optionally substituted with 1 to 5 halogen atom(s).

2 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

R represents a hydrogen atom or an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 1 and R 2 each independently represent a hydrogen atom or an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 3 , R 4 , and R 6 each independently represent a hydrogen atom, a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 5 represents (i) a hydrogen atom, or (ii) an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, a hydroxy group, a phenyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, and an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E; and

ring B represents a bicyclic ring optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, and a cyano group.

3 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

R represents a hydrogen atom or an alkyl group;

R 1 and R 2 each independently represent a hydrogen atom or an alkyl group;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle;

R 3 , R 4 , and R 6 each independently represent a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group;

R 5 represents (i) a hydrogen atom, or (ii) an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, a hydroxy group, a phenyl group, and an alkoxy group;

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E; and

ring B represents a bicyclic ring optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, and a cyano group.

4 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

the compound has a structure represented by the following general formula (I-1):

R represents a hydrogen atom or an alkyl group;

R 1 and R 2 each independently represent a hydrogen atom or an alkyl group;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle;

R 3 represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group;

R 4 and R 6 each independently represent a hydrogen atom, an alkyl group, or an alkoxy group; and

R 5 represents a hydrogen atom or an alkyl group.

5 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

R represents a hydrogen atom;

R 1 and R 2 each independently represent a hydrogen atom or an alkyl group;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle;

R 3 represents an alkyl group;

R 4 represents an alkyl group;

R 5 represents an alkyl group; and

R 6 represents a hydrogen atom.

6 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

A has a structure represented by any one of the following formulae (II-1) to (II-3):

wherein:

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

X 1 and X 2 each independently represent CR 9 or a nitrogen atom;

R 9 each independently represents a hydrogen atom, a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or a cyano group; and

ring D represents a 5 to 6 membered carbocycle or a 5 to 6 membered heterocycle, each of which is optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, and a cyano group.

7 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

A has a structure represented by any one of the following formulae (II-1-1) to (II-3-4):

wherein:

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

X 1 and X 2 each independently represent CR 9 or a nitrogen atom;

Y 1 , Y 2 , Y 3 , and Y 4 each independently represent CR 10 or a nitrogen atom;

R 9 and R 10 each independently represent a hydrogen atom, a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or a cyano group;

Q 1 and Q 2 each independently represent CR 11 R 12 , NR 13 , an oxygen atom, a sulfur atom, SO, or SO 2 ;

R 11 and R 12 each independently represent a hydrogen atom, a halogen atom, or an alkyl group;

R 13 each independently represents a hydrogen atom or an alkyl group;

Z represents NR 14 , an oxygen atom, or a sulfur atom;

R 14 represents a hydrogen atom or an alkyl group;

Q 3 represents (CU 1 U 2 ) n ;

U 1 and U 2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group; and

n represents 1, 2, or 3.

8 . The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

A has a structure represented by the following formula (II-1-1):

wherein:

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle;

X 1 and X 2 each independently represent CR 9 ;

any one of Y 1 , Y 2 , Y 3 , and Y 4 represents a nitrogen atom, and the other three each independently represent CR 10 ;

R 9 each represents a hydrogen atom; and

R 10 each independently represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group.

9 . The compound according to claim 1 represented by the following general formula (I-1-1) or a pharmaceutically acceptable salt thereof:

wherein:

R represents a hydrogen atom or an alkyl group;

R 1 and R 2 each independently represent a hydrogen atom or an alkyl group;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle;

R 3 , R 4 , and R 6 each independently represent a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group;

R 5 represents (i) a hydrogen atom, or (ii) an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from the group consisting of a halogen atom, a hydroxy group, a phenyl group, and an alkoxy group;

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle optionally substituted with 1 to 5 substituent(s) independently selected from Group E;

R 10 represents a hydrogen atom, a halogen atom, an alkyl group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, an alkoxy group optionally substituted with 1 to 5 substituent(s) independently selected from Group E, or a cyano group; and

Group E represents a group consisting of a halogen atom, a hydroxy group, and an alkoxy group optionally substituted with 1 to 5 halogen atom(s).

10 . The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein

R represents a hydrogen atom or an alkyl group;

R 1 and R 2 each independently represent a hydrogen atom or an alkyl group;

or R 1 and R 2 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle;

R 3 represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group;

R 4 represents a hydrogen atom or an alkyl group;

R 5 represents an alkyl group;

R 6 represents a hydrogen atom;

R 7 and R 8 each independently represent a hydrogen atom or an alkyl group;

or R 7 and R 8 are combined with the carbon atom to which they are attached to form a monocyclic carbocycle; and

R 10 represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group.

11 . The compound according to claim 1 selected from the group consisting of

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2,2-difluoro-6,7-dihydro-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-f][1,4]oxazepin-8 (9H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2,2-difluoro-6,7-dihydro-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-f][1,4]oxazepin-8 (9H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-9-ethyl-2,2-difluoro-8,9-dihydro-[1,3]dioxolo[4′,5′:3,4]benzo[1,2-f][1,4]oxazepin-7 (6H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-9-ethyl-2,2-difluoro-8,9-dihydro-[1,3]dioxolo[4′,5′:3,4]benzo[1,2-f][1,4]oxazepin-7 (6H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,5,7,8,9-hexahydro-4H-indeno[5,6-f][1,4]oxazepin-4-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,5,7,8,9-hexahydro-4H-indeno[5,6-f][1,4]oxazepin-4-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,7,8,9,10-hexahydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,7,8,9,10-hexahydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4,8,9,10,11-hexahydronaphtho[1,2-f][1,4]oxazepin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4,8,9,10,11-hexahydronaphtho[1,2-f][1,4]oxazepin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,5,8,9,10-hexahydro-4H-indeno[5,4-f][1,4]oxazepin-4-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,5,8,9,10-hexahydro-4H-indeno[5,4-f][1,4]oxazepin-4-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,8,9,10,11-hexahydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,8,9,10,11-hexahydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-8-methyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-8-methyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-1,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-1,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydronaphtho[1,2-f][1,4]oxazepin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydronaphtho[1,2-f][1,4]oxazepin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-8,9-dihydro-[1,4]oxazepino [7,6-h]quinolin-10 (11H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-8,9-dihydro-[1,4]oxazepino [7,6-h]quinolin-10 (11H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydro-[1,4]oxazepino [6,7-f]quinolin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydro-[1,4]oxazepino [6,7-f]quinolin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydro-[1,4]oxazepino [7,6-c]quinolin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydro-[1,4]oxazepino [7,6-c]quinolin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-1,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-1,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-1-methyl-1,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-1-methyl-1,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-2-methyl-2,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-2-methyl-2,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-1,3,4,9,10,11-hexahydro-2H-pyrimido[1′,2′: 1,6]pyrido[2,3-f][1,4]oxazepin-2-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-h]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-h]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-f]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-f]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-7-fluoro-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-7-fluoro-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-1-methyl-1,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-1-methyl-1,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-2-methyl-2,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-2-methyl-2,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-g]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-g]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-7-fluoro-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-7-fluoro-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-f]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-f]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

ethyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl) propanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl) propanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((S)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((S)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate;

3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((2,2-dimethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((2,2-dimethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2,2-dimethyl-6,7-dihydro-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-f][1,4]oxazepin-8 (9H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2,2-dimethyl-6,7-dihydro-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-f][1,4]oxazepin-8 (9H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-h]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(3-((2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate;

3-(3-((2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-1,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-1,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-1-methyl-1,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-1-methyl-1,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2-methyl-2,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2-methyl-2,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(3-(((R)-7-chloro-2-ethyl-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate;

3-(3-(((R)-7-chloro-2-ethyl-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

methyl 3-(3-(((R)-7-chloro-2-ethyl-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate;

3-(3-(((R)-7-chloro-2-ethyl-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(3-(((R)-10-chloro-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methoxy-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methoxy-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,7,8-tetrahydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,7,8-tetrahydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-9,9-dioxide-2,3,7,8-tetrahydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-9,9-dioxide-2,3,7,8-tetrahydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3-(((R)-2-methyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl) propanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3-(((R)-2-methyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl) propanoic acid;

methyl 3-(3-((3′H-spiro[cyclopropane-1,2′-[1,4]oxazepino [7,6-g]quinoline]-4′ (5′H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate;

3-(3-((3′H-spiro[cyclopropane-1,2′-[1,4]oxazepino [7,6-g]quinoline]-4′ (5′H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3-((2-propyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl) propanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3-((2-propyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl) propanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl)-2,2-dimethylpropanoic acid;

methyl 3-(4-chloro-3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate;

3-(4-chloro-3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methoxyphenyl)-2,2-dimethylpropanoate;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid;

methyl 3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(1-methyl-1H-benzo[d][1,2,3]triazol-5-yl) propanoate;

3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(1-methyl-1H-benzo[d][1,2,3]triazol-5-yl) propanoic acid;

methyl 1-((1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl) (3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)methyl)cyclopentane-1-carboxylate;

1-((1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl) (3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)methyl)cyclopentane-1-carboxylic acid;

methyl 1-((1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl) (3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)methyl)cyclobutane-1-carboxylate;

1-((1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl) (3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)methyl)cyclobutane-1-carboxylic acid;

methyl 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((S)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoate; and

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((S)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid or a pharmaceutically acceptable salt thereof.

12 . The compound according to claim 1 selected from the group consisting of

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2,2-difluoro-6,7-dihydro-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-f][1,4]oxazepin-8 (9H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-9-ethyl-2,2-difluoro-8,9-dihydro-[1,3]dioxolo[4′,5′:3,4]benzo[1,2-f][1,4]oxazepin-7 (6H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,5,7,8,9-hexahydro-4H-indeno[5,6-f][1,4]oxazepin-4-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,7,8,9,10-hexahydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4,8,9,10,11-hexahydronaphtho[1,2-f][1,4]oxazepin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,5,8,9,10-hexahydro-4H-indeno[5,4-f][1,4]oxazepin-4-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,8,9,10,11-hexahydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-8-methyl-2,3-dihydro-[1,4]oxazepino [7,6-b]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-1,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydronaphtho[1,2-f][1,4]oxazepin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-8,9-dihydro-[1,4]oxazepino [7,6-h]quinolin-10 (11H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydro-[1,4]oxazepino [6,7-f]quinolin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-3,4-dihydro-[1,4]oxazepino [7,6-c]quinolin-2 (1H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-1,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-1-methyl-1,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-7-ethyl-2-methyl-2,7,8,10-tetrahydro-9H-[1,4]oxazepino [7,6-g]indazol-9-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-4-ethyl-1,3,4,9,10,11-hexahydro-2H-pyrimido[1′,2′: 1,6]pyrido[2,3-f][1,4]oxazepin-2-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-h]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-f]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-7-fluoro-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-1-methyl-1,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-8-ethyl-2-methyl-2,5,7,8-tetrahydro-6H-[1,4]oxazepino [6,7-f]indazol-6-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-g]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-7-fluoro-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-f]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl) propanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((S)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((2,2-dimethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2,2-dimethyl-6,7-dihydro-[1,3]dioxolo[4′,5′:4,5]benzo[1,2-f][1,4]oxazepin-8 (9H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-h]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(3-((2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-1,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-1-methyl-1,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-6-ethyl-2-methyl-2,6,7,9-tetrahydro-8H-[1,4]oxazepino [7,6-f]indazol-8-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(3-(((R)-7-chloro-2-ethyl-2,3-dihydronaphtho[2,1-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(3-(((R)-7-chloro-2-ethyl-2,3-dihydronaphtho[2,3-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(3-(((R)-10-chloro-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methoxy-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3,7,8-tetrahydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-9,9-dioxide-2,3,7,8-tetrahydrothieno[2′,3′: 4,5]benzo[1,2-f][1,4]oxazepin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3-(((R)-2-methyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl) propanoic acid;

3-(3-((3′H-spiro[cyclopropane-1,2′-[1,4]oxazepino [7,6-g]quinoline]-4′ (5′H)-yl)methyl)-4-methylphenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethyl-3-(4-methyl-3-((2-propyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl) propanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl)-2,2-dimethylpropanoic acid;

3-(4-chloro-3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)phenyl)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoic acid;

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid;

3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-(1-methyl-1H-benzo[d][1,2,3]triazol-5-yl) propanoic acid;

1-((1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl) (3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)methyl)cyclopentane-1-carboxylic acid;

1-((1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl) (3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino [7,6-g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)methyl)cyclobutane-1-carboxylic acid; and

3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((S)-2-ethyl-2,3-dihydro-[1,4]oxazepino [6,7-c]isoquinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid

or a pharmaceutically acceptable salt thereof.

13 . A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14 . A method for prevention, alleviation, and/or treatment of a disease which is improved by the inhibition of Keap1, comprising administering the pharmaceutical composition according to claim 13 to a subject in need thereof.

15 . The pharmaceutical composition according to claim 14 , wherein the disease which is improved by the inhibition of Keap1 is a renal disease.

16 . The compound according to claim 1 , which is 3-(1,4-dimethyl-1H-benzo [d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino[7,6-g]quinolin- 4(5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid,

or a pharmaceutically acceptable salt thereof.

17 . The compound according to claim 1 , which is 3-(1,4-dimethyl-1H-benzo [d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino[6,7-c]isoquinolin- 4(5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid,

or a pharmaceutically acceptable salt thereof.

18 . The compound according to claim 1 , which is 3-(1,4-dimethyl-1H-benzo [d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino[6,7-c]quinolin- 4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid,

or a pharmaceutically acceptable salt thereof.

19 . The compound according to claim 1 , which is 3-(1,4-dimethyl-1H-benzo [d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-10-methoxy-2,3-dihydro-[1,4]oxazepino[7,6- g]quinolin-4 (5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid,

or a pharmaceutically acceptable salt thereof.

20 . The compound according to claim 1 , which is 1-((1,4-dimethyl-1H-benzo [d][1,2,3]triazol-5-yl)(3-(((R)-2-ethyl-2,3-dihydro-[1,4]oxazepino[7,6-g]quinolin-4(5H)- y1)methyl)-4-methylphenyl)methyl)cyclobutane-1-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Dec 7, 2022
From: UBE INDUSTRIES, LTD.
To: UBE CORPORATION
Reel/Frame 062080/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: KOMORI, KEN-ICHI; NISHIYAMA, HAYATO; KINOSHITA, NAOYA; WADA, YUKINORI; MORISHITA, KOUSUKE; NINOMIYA, AKISHI; SHIRAISHI, YUUSUKE; ONUMA, KAZUHIRO; OGI, SAYAKA; KAWADA, HIROYOSHI; KIMURA, TOMIO
To: UBE INDUSTRIES, LTD.
Reel/Frame 058446/0345 →
Priority Claims (1)
JP 2019-102529 · May 31, 2019 · national
Continuity (1)
Related Publication 20220259223A1 · Aug 18, 2022
References Cited (68)
US 20170210736A1 · Kuroda et al. · 2017 [cited by applicant]
US 20180179187A1 · Kerns et al. · 2018 [cited by applicant]
US 20200031846A1 · Brooks et al. · 2020 [cited by applicant]
US 20200055874A1 · Barbay et al. · 2020 [cited by applicant]
US 20230024995A1 · Miyabe et al. · 2023 [cited by applicant]
CN 108112251A · 2018 [cited by applicant]
EA 030431B1 · 2018 [cited by applicant]
RU 2017105836A · 2018 [cited by applicant]
WO WO2015092713A1 · 2015 [cited by applicant]
WO WO2016203400A1 · 2016 [cited by applicant]
WO WO2016203401A1 · 2016 [cited by applicant]
WO WO2016202253A1 · 2016 [cited by examiner]
WO WO2017060854A1 · 2017 [cited by applicant]
WO WO2017060855A1 · 2017 [cited by applicant]
WO WO2018104766A1 · 2018 [cited by applicant]
WO WO2018109641A1 · 2018 [cited by applicant]
WO WO2018109642A1 · 2018 [cited by applicant]
WO WO2018109643A1 · 2018 [cited by applicant]
WO WO2018109646A1 · 2018 [cited by applicant]
WO WO2018109647A1 · 2018 [cited by applicant]
WO WO2018109648A1 · 2018 [cited by applicant]
WO WO2018109649A1 · 2018 [cited by applicant]
WO WO2018181345A1 · 2018 [cited by applicant]
WO WO2019116230A1 · 2019 [cited by applicant]
WO WO2019116231A1 · 2019 [cited by applicant]
WO WO2019224667A1 · 2019 [cited by applicant]
WO WO2020041169A2 · 2020 [cited by applicant]
WO WO2020116660A1 · 2020 [cited by applicant]
WO WO2020165776A1 · 2020 [cited by applicant]
WO WO2021002473A1 · 2021 [cited by applicant]
WO WO2021170774A1 · 2021 [cited by applicant]
International Search Report issued Apr. 29, 2019 in PCT/JP2020/021426 (submitting English translation only), citing documents AA-AC, AE-AH and AY therein, 3 pages. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued Nov. 16, 2021 in PCT/JP2020/021426 (submitting English translation only), citing documents AE-AH and … [cited by applicant]
Tom D. Heightman, et al., “Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2… [cited by applicant]
Ilaria Bellezza, et al., “Nrf2-Keap1 Signaling in Oxidative and Reductive Stress” BBA Molecular Cell Research, vol. 1865, 2018, pp. 721-733. [cited by applicant]
Melanie P. Chin, et al., “Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Ki… [cited by applicant]
Rieko Shimozono, et al., “Nrf2 Activators Attenuate the Progression of Nonalcoholic Steatohepatitis-Related Fibrosis in a Dietary Rat Models” Molecular Pharmacology, vol. 84, Jul. 2013, pp. 62-70. [cited by applicant]
Meng-Chen Lu, et al., “An Inhibitor of the Keap1-Nrf2 Protein-Protein Interaction Protects NCM460 Colonic Cells and Alleviates Experimental Colitis” Scientific Reports, vol. 6, 26585, 2016, pp. 1-13. [cited by applicant]
John G. Yonchuk, et al., “Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress” The Journa… [cited by applicant]
Vitali Alexeev, et al., “Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound” Molecular Cancer Therapeutics, vol. 13, No. 12, Dec. 2014, pp. 2968-2… [cited by applicant]
Ulf Schulze-Topphoffa, et al., “Dimethyl Fumarate Treatment Induces Adaptive and Innate Immune Modulation Independentof Nrf2” Proceeding of the National Academy of Sciences of the United States of America, vol. 113, No.… [cited by applicant]
Junnan Chen, “Dysfunction of Nrf-2 in CF Epithelia Leads to Excess Intracellular H2O2 and Inflammatory Cytokine Production” Plos One, vol. 3, No. 10, Oct. 2008, e3367 pp. 1-12. [cited by applicant]
Luke M. Shelton, et al., “Role of Nrf2 in Protection Against Acute Kidney Injury” Kidney International, vol. 84, 2013, pp. 1090-1095. [cited by applicant]
Reuben Howden, “Nrf2 and Cardiovascular Defense” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 104308, 2013, pp. 1-10. [cited by applicant]
Takafumi Mimoto, et al., “Impaired Antioxydative Keap1/Nrf2 System and the Downstream Stress Protein Responses in the Motor Neuron of ALS Model Mice” Brain Research, vol. 1446, 2012, pp. 109-118. [cited by applicant]
Vincent Paupe, et al., “Impaired Nuclear Nrf2 Translocation Undermines the Oxidative Stress Response in Friedreich Ataxia” Plos One, vol. 4, Issued 1, e4253, Jan. 2009, pp. 1-11. [cited by applicant]
Maya S. Bitar, et al., “Decline in DJ-1 and Decreased Nuclear Translocation of Nrf2 in Fuchs Endothelial Corneal Dystrophy” Investigative Ophthalmology & Visual Science, vol. 53, No. 9, Aug. 2012, pp. 5806-5813. [cited by applicant]
Matthias Schäfer, et al., “Nrf2 Establishes a Glutathione-Mediated Gradient of UVB Cytoprotection in the Epidermis” Genes and Development, vol. 24, 2010, pp. 1045-1058. [cited by applicant]
Jung-Hyun Kim, et al., “NRF2-Mediated Notch Pathway Activation Enhances Hematopoietic Reconstitution Following Myelosuppressive Radiation” The Journal of Clinical Investigation, vol. 124, No. 2, Feb. 2014, pp. 730-741. [cited by applicant]
Christina Lisk, et al., “Nrf2 Activation: A Potential Strategy for the Prevention of Acute Mountain Sickness” Free Radical Biology and Medicine, vol. 63, Oct. 2013, pp. 264-273. [cited by applicant]
Thomas G. Davies, et al., “Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragm… [cited by applicant]
Office Action issued Jul. 8, 2024, in corresponding Chinese Patent Application No. 202080055155.9 (with English Translation), 9 pages. [cited by applicant]
Office Action issued Jul. 11, 2024, in corresponding Mexican Patent Application No. MX/a/2021/01 4680 (with English Translation), 8 pages. [cited by applicant]
Office Action issued Aug. 15, 2024, in corresponding Russian Patent Application No. 2021135307 (with English Translation) citing documents 24 and 25 therein, 20 pages. [cited by applicant]
Office Action issued Aug. 5, 2024, in corresponding Indian Patent Application No. 202117057337 (with English Translation), 2 pages. [cited by applicant]
Dayson G., M, Chemistry of Synthetic Drugs, 1964, pp. 12-19 (with English translation). [cited by applicant]
Bastin R.J. et al., “Salt selection and optimisation procedures for pharmaceutical new chemical entities”, Organic process research & development, 2000, V.4, N.5, pp. 427-435. [cited by applicant]
Japanese Office Action issued Apr. 2, 2024 in Japanese Patent Application No. 2021-522912 (with English translation), 7 pages. [cited by applicant]
Extended European Search Report issued Jun. 14, 2023 in European Patent Application No. 20815167.0, 5 pages. [cited by applicant]
Combined Russian Office Action and Search Report issued Oct. 19, 2023 in Russian Patent Application No. 2021135307/04(074592) (with English translation), citing documents 15-16 therein, 16 pages. [cited by applicant]
Chinese Office Action issued Nov. 1, 2023 in Chinese Patent Application No. 202080055155.9 (with English translation) citing document 17 therein, 10 pages. [cited by applicant]
Indian Office Action issued Jan. 9, 2024 in Indian Patent Application No. 202117057337, 6 pages. [cited by applicant]
Belikov, V., “Pharmaceutical Chemistry Manual”. Moscow: 4 [cited by applicant]
Kummerer, K., et al., “Pharmaceuticals in the Environment”, The Annual Review of Environment and Resources, vol. 35, 2010, pp. 57-75. [cited by applicant]
Office Action issued May 23, 2025 in the corresponding Canadian patent application No. 3142295, 4 pages. [cited by applicant]
Office Action issued Aug. 18, 2025, in the corresponding Korean patent application No. 10-2021-7042003 with machine English translation, 8 pages. [cited by applicant]
Examination report No. 1 issued Feb. 17, 2025 in the corresponding Australian patent application No. 2020283361, 3 pages. [cited by applicant]
Examination report No. 2 issued Sep. 1, 2025 in the corresponding Australian patent application No. 2020283361, 2 pages. [cited by applicant]